Tag Archives: clinical

Targeted treatment herceptin found to greatly improve long-term survival of her2-positive breast cancer patients — ScienceDaily

Published in the Journal of Clinical Oncology, the study found that Herceptin, when added to chemotherapy, improved 10-year survival from 75 percent with chemotherapy alone to 84 percent with the addition of trastuzumab. Additionally, results also demonstrated continued improvement of survival without cancer recurrence — the 10-year disease-free survival rate increased from 62 percent to 74 percent with the addition of trastuzumab. Although heart problems are recognized side effects of Herceptin, the incidence rate of such events was found to be about 3 percent and the majority of those patients recovered from the initial effects. “We have found that when Herceptin is used in combination with chemotherapy, a patient’s survival is significantly improved,” said Geyer, who serves as a senior scientific advisor to the NSABP and at Massey is the Harrigan, Haw, Luck Families Chair in Cancer Research, associate director for clinical research and member of the Developmental Therapeutics research program, as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine. …

Male, female breast cancers are not identical — ScienceDaily

Dr. Fatima Cardoso of the Champalimaud Clinical Center in Lisbon and coordinator of this study says, “This study aims to characterize the biology of this rare disease; only with this crucial knowledge will men with breast cancer be properly treated in the future, which will definitely improve both their survival and quality of life.” Of all cancers diagnosed in males, breast cancer accounts for less than one percent, and male breast cancer also accounts for less than one percent of all breast cancer diagnoses. …

First gene associated with familial glioma identified

“It is widely thought amongst the clinical community that there is no association between family history and development of glioma. Because we know very little about the contributing genetic factors, when cases occur in two or more family members, it is viewed as coincidental,” said Dr…

Practice makes perfect in cancer surgery — ScienceDaily

Using data provided by the Institute for Clinical Evaluative Sciences (ICES) the investigators studied 2,802 patients who underwent the procedure between 1994 and 2008 in Ontario and found that higher volume hospital and surgeons were associated with less post-operative complications and better overall survival. “These results are intriguing and will undoubtedly lead to some controversy in their interpretation,” says Dr. …

Early palliative care can cut hospital readmissions for cancer patients

The Duke researchers shared their findings at the Palliative Care in Oncology Symposium sponsored by the American Society of Clinical Oncology. In the new treatment model, medical oncologists and palliative care physicians partnered in a “co-rounding” format to deliver cancer care for patients admitted to Duke University Hospital’s solid tumor unit. The Duke model fostered collaboration and communication between the specialists, who met several times a day to discuss patient care…

Years after treatment for HER2-positve early stage breast cancer, trastuzumab continues to show life-altering benefit

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone. These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida…

Years after treatment for HER2-positve early stage breast cancer, trastuzumab continues to show life-altering benefit — ScienceDaily

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone. These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. “This long follow-up of patients shows that we have really altered the natural history of this disease,” says Dr…

With three first-in-human trials, therapeutic stem cell science takes a bold step

The procedure, conducted on Sept. 30 under the auspices of the Sanford Stem Cell Clinical Center at UC San Diego Health System and in collaboration with Neuralstem, Inc., a Maryland-based biotechnology firm, is the first of four in the Phase I clinical trial. …

Access to minimally invasive colon cancer surgery varies by location

A new study by researchers at the University of Michigan Comprehensive Cancer Center finds that in some parts of the country, about two-thirds of colon cancer patients will receive laparoscopic colectomy, a minimally invasive procedure to remove part of the colon. In other parts of the country, the rate was zero. …